ITPKC

Across TCGA pan-cancer cohorts, ITPKC mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ITPKC data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ITPKC mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ITPKC expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

PDAC, HNSC, and GBM are the cancer types where ITPKC mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.267	0.585	<.001	43	view →
HNSC	OS	Median	IV	0.858	0.573	.003	29	view →
GBM	DFS	Median	All	0.635	0.865	.001	19	view →
LSCC	DFS	Tertile	All	0.944	0.869	.028	6	view →
CCRCC	DFS	Median	All	0.713	0.891	.014	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ITPKC–PDAC (OS)

Open the PDAC breakdown →